SEC 13F Intelligence

Managers / Q2 2020 · view latest →

Noked Israel Ltd

CIK 0001767750 · 22 HAGEFEN ST, RAMAT HASHARON, L3, 4725422 · 972-73-780-3400

Reported Value
$140M
Q2 2020
Positions
16
Filings on Record
32
2019–present window
Filed
Aug 14, 2020
original filing

Summary

Noked Israel Ltd reported $140M in U.S.-listed holdings across 16 positions for Q2 2020.

The portfolio is heavily concentrated: TEVA alone accounts for 26.1% of reported value.

Compared with Q1 2020, the fund opened 6 new positions and exited 4.

Portfolio Metrics

Turnover
+7.0%
vs prior filed quarter
Top-10 Concentration
+96.8%
share of reported value
Largest Position
+26.1%
Teva Pharmaceutical Inds
New / Exited
6 / 4
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q1 ’19: $96MQ1 ’19Q2 ’19: $82MQ3 ’19: $95MQ4 ’19: $89MQ1 ’20: $56MQ1 ’20Q2 ’20: $140MQ3 ’20: $151MQ4 ’20: $243MQ1 ’21: $307MQ1 ’21Q2 ’21: $401MQ3 ’21: $425MQ4 ’21: $407MQ1 ’22: $329MQ1 ’22Q2 ’22: $435MQ3 ’22: $411MQ4 ’22: $262MQ1 ’23: $230MQ1 ’23Q2 ’23: $292MQ3 ’23: $330MQ4 ’23: $379MQ1 ’24: $372MQ1 ’24Q2 ’24: $362MQ3 ’24: $458MQ4 ’24: $508MQ1 ’25: $436MQ1 ’25Q2 ’25: $542MQ3 ’25: $639MQ4 ’25: $624MQ1 ’26: $677MQ1 ’26filingsflow.com

Portfolio Composition

By security type
Common Stock: 38.3%ADR: 27.3%Other: 19.3%US DOMESTIC: 15.0%
  • Common Stock · 38.3% · $54M
  • ADR · 27.3% · $38M
  • Other · 19.3% · $27M
  • US DOMESTIC · 15.0% · $21M

Quarter-over-Quarter Changes full breakdown →

vs Q1 2020 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
WIX COM LTDNEW+82.1K82.1K+$21M$21M
CEVACEVA INCNEW+427.1K427.1K+$16M$16M
FIVERR INTL LTDNEW+174.6K174.6K+$13M$13M
GOOGALPHABET INCNEW+1.2K1.2K+$2M$2M
SPDR S&P 500 ETF TRNEW+2.6K2.6K+$1M$1M
ISHARES TRNEW+1.4K1.4K+$487,000$487,000
NTRNUTRIEN LTDSOLD OUT−90.0K0−$3M$0
ORAORMAT TECHNOLOGIES INCSOLD OUT−30.0K0−$2M$0

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q2 2020

16 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1TEVATEVA PHARMACEUTICAL INDS LTDhistory →SPONSORED ADS26.07%$36M2.96M
2SEDGSOLAREDGE TECHNOLOGIES INChistory →COM17.41%$24M175.4K
3WIX COM LTDNOTE 7/015.05%$21M82.1K
4CEVACEVA INChistory →COM11.43%$16M427.1K
5FIVERR INTL LTDORD SHS9.21%$13M174.6K
6RADA ELECTR INDS LTDCOM PAR NEW7.11%$10M1.52M
7MSFTMICROSOFT CORPhistory →COM6.93%$10M47.7K
8AMZNAMAZON COM INChistory →COM1.32%$2M670
9GOOGALPHABET INChistory →CAP STK CL C1.21%$2M1.2K
10G WILLI FOOD INTL LTDORD1.07%$1M95.8K
11BABAALIBABA GROUP HLDG LTDhistory →SPONSORED ADS1.07%$1M6.9K
12SPDR S&P 500 ETF TRPUT1.05%$1M2.6K
13ISHARES TRPUT0.35%$487,0001.4K
14ELLOMAY CAPITAL LTDSHS0.30%$421,00020.0K
15XTL BIOPHARMACEUTICALS LTDSPONSORED ADR NE0.23%$316,000198.9K
16ITMRITAMAR MED LTDSPONSORED ADS0.20%$274,00014.8K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$677M13May 14, 202613F-HRchanges · EDGAR ↗
Q4 2025$624M14Feb 13, 202613F-HRchanges · EDGAR ↗
Q3 2025$639M14Nov 13, 202513F-HRchanges · EDGAR ↗
Q2 2025$542M12Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$436M15May 13, 202513F-HRchanges · EDGAR ↗
Q4 2024$508M16Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$458M18Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$362M15Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$372M22May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$379M31Feb 15, 2024RESTATEMENTchanges · EDGAR ↗
Q3 2023$330M28Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$292M35Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$230M22May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$262M27Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$411M50Dec 27, 2022RESTATEMENTchanges · EDGAR ↗
Q2 2022$435M48Aug 12, 202213F-HRchanges · EDGAR ↗
Q1 2022$329M42May 13, 202213F-HRchanges · EDGAR ↗
Q4 2021$407M45Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$425M46Nov 12, 202113F-HRchanges · EDGAR ↗
Q2 2021$401M35Aug 12, 202113F-HRchanges · EDGAR ↗
Q1 2021$307M33May 12, 202113F-HRchanges · EDGAR ↗
Q4 2020$243M27Feb 12, 202113F-HRchanges · EDGAR ↗
Q3 2020$151M22Nov 13, 202013F-HRchanges · EDGAR ↗
Q2 2020$140M16Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$56M14May 27, 2020RESTATEMENTchanges · EDGAR ↗
Q4 2019$89M58Feb 18, 202013F-HRchanges · EDGAR ↗
Q3 2019$95M38Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019$82M81Aug 15, 201913F-HRchanges · EDGAR ↗
Q1 2019$96M72May 13, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.